Soligenix (SNGX) Stock Price, News & Analysis

Company Overview

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing treatments for rare diseases and medical conditions with limited therapeutic options. The company’s programs are organized around two principal areas: specialized therapeutics for inflammatory and dermatologic disorders, and vaccines and countermeasures for serious infectious diseases and biodefense applications.

Its lead product candidate, HyBryte™ (synthetic hypericin), is an investigational photodynamic therapy being developed for cutaneous T-cell lymphoma, a form of non-Hodgkin lymphoma that primarily affects the skin. Soligenix has also developed SGX301, the former designation for HyBryte, and maintains additional research programs involving oral and systemic therapies for inflammatory diseases. The company’s biodefense portfolio includes RiVax®, a recombinant ricin toxin vaccine candidate, and ThermoVax®, a technology designed to improve the thermal stability of vaccines and other biologic products.

Headquartered in Princeton, New Jersey, Soligenix conducts research and clinical development primarily in the United States while pursuing opportunities for broader application and commercialization of its technologies. The company is led by Christopher J. Schaber, Ph.D., who serves as president and chief executive officer. Soligenix’s products remain subject to clinical development and regulatory review, and availability may vary by program and jurisdiction.

Key Stats

• Today's Range: $0.38 to $0.39
• 50-Day Range: $0.36 to $0.41
• 52-Week Range: $0.28 to $1.97
• Volume: 228,592 shs
• Average Volume: 2.73 million shs
• Market Capitalization: $5.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Soligenix Stock Analysis - MarketRank™

Soligenix scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Soligenix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Soligenix has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Soligenix are expected to grow in the coming year, from ($0.55) to ($0.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Soligenix is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Soligenix is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Soligenix has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.45% of the float of Soligenix has been sold short.

Short Interest Ratio / Days to Cover

Soligenix has a short interest ratio ("days to cover") of 0.68, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Soligenix has recently increased by 1.40%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Soligenix does not currently pay a dividend.

Dividend Growth

Soligenix does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Soligenix this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Soligenix insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.91% of the stock of Soligenix is held by insiders.

Percentage Held by Institutions

3.60% of the stock of Soligenix is held by institutions.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 9/24/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SNGX
• CIK: 812796
• Web: www.soligenix.com
• Phone: (609) 538-8200
• Fax: 609-452-6467
• Employees: 14
• Year Founded: 1987

Profitability

• EPS (Trailing Twelve Months): ($0.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -180.25%
• Return on Assets: -107.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.77
• Quick Ratio: 2.77

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.52 per share
• Price / Book: 0.74

Miscellaneous

• Outstanding Shares: 14,824,000
• Free Float: 14,541,000
• Market Cap: $5.73 million
• Optionable: Not Optionable
• Beta: 1.92